S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute... ( SINGAPORE Nov. 27 /- S*BIO Pte Lt...)

S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute Leukemias

Date:11/27/2007

SINGAPORE, Nov. 27 /PRNewswire/ -- S*BIO Pte Ltd today announced the expansion of its proprietary pipeline, with its third development candidate, SB1317. This is a novel orally-available small molecule compound targeted for the treatment of acute leukemias.

SB1317 is designed to selectively inhibit major signalling pathways involving Flt3 and CDK, which impact disease progression in acute leukemias. Flt3 mutations are the most frequent genetic alterations reported in acute myeloid leukemia (AML) patients and are associated with a poor prognosis. In addition, over-expression of wild type Flt3 has been found in acute lymphoblastic leukemia (ALL) patients. Cyclin-dependent kinases or CDKs play important roles in cell cycle control. By inhibiting both Flt3 and CDK kinases, SB1317 is uniquely positioned as a "first-in-class" compound to treat relapsed and refractory acute leukemias. SB1317 has already entered preclinical development.

"The ability to maintain long-term control in AML and ALL remains one of the most significant unmet medical needs in the adult leukemia market. SB1317 has been designed with this in mind, and we believe it has the potential to become a first of its kind Flt3 inhibitor to specifically target this group of patients," said Dr. Jan-Anders Karlsson, CEO of S*BIO, "With its ideal profile for treating relapsed and refractory AML and ALL, SB1317 provides an opportunity for S*BIO to expand its portfolio of new targeted therapies for hematological disorders."

Approximately 300,000 new cases of leukemia are diagnosed worldwide each year, and there are about 36,000 new cases of acute leukemia in the seven major pharmaceutical markets*. Acute leukemia is characterized by rapid growth and accumulation of immature blood cells in the bone marrow. This results in fewer normal blood cells. Relapse rates following conventional leukemia treatments remain high and limited treatment options exist for patients who relapse after standard
'/>"/>

SOURCE S*BIO Pte Ltd
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine news :

1. Longaberger Expands Horizon of Hope Campaign to Build Support for American Cancer Societys Breast Cancer Initiatives
2. Rohm and Haas Expands in India
3. US Med-Equip Expands Corporate Support Center
4. Concentra Expands Horizon Air Employee Health Program With On-Site Clinic
5. Regional Center of Orange County Expands Family Support Resources to Meet Growing Needs
6. Maimonides Expands Circulation of Physicians Practice Journal to Staten Island Doctors
7. Specialty Blades, Inc. Expands Management Team With New VP Engineering
8. CRH Medical expands Las Vegas operations
9. ISTA Pharmaceuticals Expands Its Pipeline in Allergy Treatments
10. Bipartisan Bill Expands Health Care Access for Small Businesses
11. ABR-Affinity BioReagents Expands 100% Quality Guarantee

Post Your Comments:

(Date:11/9/2009)...China, Nov. 9 /PRNewswire-FirstCall/ - Hard To Tre...nced today that Novartis, a US$41 billion internat...e in HTDS, H1N1 Vaccine partner, Zhejiang Tianyuan... Novartis of Switzerland will begin a five-year, $...any will dramatically increase its investment in i...

(Date:11/9/2009)... Fast food chains are often blamed for th...poll by Fitness.com.au however finds that 80% of p...nsibility. , (PRWEB) Nove...nd video games were behind Australia’s obesi...an just innocent bystanders. A recent survey commi...

(Date:11/9/2009)... Tomorrow may be too late when it comes t...cording to TOPS Club, Inc. (Take Off Pounds Sensib...n. , (Vocus) November 9, ...preventing or improving a diabetes condition, acco...), the nonprofit weight-loss support organization....

(Date:11/9/2009)... Course, to be Offered in April 2010, Pro... Cambridge, MA (Vocus) Nove...for Human Rights (PHR) first inspected a suspected...realized he would need a team of experts to help i...ite properly was a key first step in securing evid...

(Date:11/9/2009)... New study highlights positive influence ... Rosemont, IL (Vocus) November 9, 2...ealth decreases. Recent research has highlighted t...to help prevent these issues. However, a new study...ts Health: A Multidisciplinary Approach reveals t...

Breaking Medicine News(10 mins):Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 2 Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 3 Health News:Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million 4 Health News:Fitness.com.au Poll Finds 80% Blame Parents For Our Overweight Kids 2 Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 2 Health News:Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says 3 Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 2 Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 3 Health News:Physicians for Human Rights Offers Training in Crime Scene Documentation 4 Health News:High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes 2

[0] Novartis to Acquire Majority Stake in Hard to Treat Diseases' (HTDS.PK) China Subsidiary H1N1 Vaccine Partner for US$125 Million [0] Fitness.com.au Poll Finds 80% Blame Parents For Our Overweight Kids [0] Diabetes Prevention Is the Best Remedy, TOPS Medical Expert Says [0] Physicians for Human Rights Offers Training in Crime Scene Documentation [0] High Impact Sports Participation May Improve Bone Mineral Density in Mature Athletes

... China, Nov. 7 /Xinhua-PRNewswire-FirstCall/ -- Ch...lletin Board: CPHI), which,develops, manufactures,...ceutical products in China, today announced financ...lion Revenue for nine months ended September 30, u...

... health plans evaluated based on quality of care, ...oup and The,National Committee for Quality Assuran... of America,s Best Health Plans on USNews.com. Lau... provides,comprehensive rankings and important con...

...Fraxel laser treatment highlighted in several podi...gic Surgery,s Annual Meeting, ORLANDO, Fla., Nov....ctional resurfacing and market leader of aesthetic...ed at the,American Society for Dermatologic Surger...

...e brand with mangosteen BioActiveX3 Complex(TM) fe...chnology in self-adjusting ...nutrition leader XanGo,LLC, today announced the of...ingredients from the mangosteen delivered through,...

.... 7 NutraCea (OTC Bulletin Board:,NTRZ), a world ...arch and,technology, today announced financial res...8., Net revenues for the 2008 third quarter incre...venues from the,Company,s NutraCea segment and $7....

..., Mich., Nov. 7 The,patient-centered medical home... coverage will be among the topics at the annual "...igan State Medical Society (MSMS),on Tuesday, Nov....of the emerging health care model that ensures coo...

China Pharma Holdings, Inc. Reports Third Quarter 2008 Financial Results and Corporate Updates U.S. News Media Group and NCQA Release 2008 Rankings for America's Best Health Plans Fraxel(R) Laser Systems Shown to Provide Superior Results Compared to 'Pseudo Fractional' Laser Technologies XanGo Introduces Glimpse(TM) Intuitive Skin Care NutraCea Announces Third Quarter 2008 Financial Results 'Best Minds, Best Practices' in Medicine Conference on Nov. 11

(Date:11/9/2009)...K, Nov. 9 MISSION Skincare®, ...star Serena Williams, soccer professional Mia Hamm...g "Active Lifestyle Skincare Destinations" in the ...ions across the country beginning this week. Stock...oducts, MISSION and CVS/pharmacy have set out to e...

(Date:11/9/2009)... Mass., Nov. 9 Groundbreaking arti...gement, for the first time explore, in depth, th...s for health care providers and its potential bene...es, University of Washington authors, Sunil Aggarw... Scientist Training Program and who conducted the ...

(Date:11/9/2009)...LE, Md., Nov. 9 OriGene Technologi...logy in Sweden has adopted its VERIFY Tagged Antig...ein Atlas program. This program is funded by the K...to explore the human proteome systematically using...ty mono-specific antibodies in a high throughput m...

Breaking Medicine Technology:Glamour Magazine Woman of the Year and MISSION Skincare Co-Founder, Serena Williams, Teams Up with CVS/pharmacy to Launch National 'Active Lifestyle Skincare Destinations' 2 Glamour Magazine Woman of the Year and MISSION Skincare Co-Founder, Serena Williams, Teams Up with CVS/pharmacy to Launch National 'Active Lifestyle Skincare Destinations' 3 Medicinal Use of Marijuana: Past, Present and Future...A Fresh Look by Experts in the Field 2 Royal Institute of Technology Adopts OriGene Over-Expression Lysates in Human Proteome Atlas Program 2 JDRF award supports study of potential target for blocking type 1 diabetes 56008 1 JDRF award supports study of potential target for blocking type 1 diabetes 56008 2 DNA mutations linked to diabetes 9759 1 Hill Rom and Radianse Announce Partnering Agreement to Integrate Location Sensing Technology into NaviCare 28R 29 Nurse Call 56004 1 Hill Rom and Radianse Announce Partnering Agreement to Integrate Location Sensing Technology into NaviCare 28R 29 Nurse Call 56004 2 Hill Rom and Radianse Announce Partnering Agreement to Integrate Location Sensing Technology into NaviCare 28R 29 Nurse Call 56004 3 Hill Rom and Radianse Announce Partnering Agreement to Integrate Location Sensing Technology into NaviCare 28R 29 Nurse Call 56004 4

[0] Glamour Magazine Woman of the Year and MISSION Skincare Co-Founder, Serena Williams, Teams Up with CVS/pharmacy to Launch National 'Active Lifestyle Skincare Destinations'[0] Medicinal Use of Marijuana: Past, Present and Future...A Fresh Look by Experts in the Field [0] Royal Institute of Technology Adopts OriGene Over-Expression Lysates in Human Proteome Atlas Program

...s Overall Psychological Toll Is Greater Than for A...Pa., May 17, 2007 /PRNewswire/ -- Nearly three out...cent) responding to a,new nationwide survey say no...urthermore, they describe UC as disruptive when it...cent), their sexual,relations (75 percent) and the...

...USALEM--(BUSINESS WIRE)--May 17, 2007 - BioLineRx ...nt company, announced today,that abstracts contain...linical trails of BL-1020, first in class GABA-enh...enia, have been,accepted for poster presentations ...will be presented at the following,conferences:, -...

Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many,Aspects of Daily Life BioLineRx Presents Phase I Clinical Data of BL-1020 at Upcoming,Clinical Conferences

CA-125 Enzyme Immunoassay Test Kit

Immulite PAP

Mosaic

...s a neurosurgical OR that fully integrates all the...cessary to treat complicated neurosurgical cases. ... performed in a workflow optimized manner. Pre-tes...BrainSUITE iMRI guarantees rapid implementation in...

Medicine Products:

CA-125 Enzyme Immunoassay Test Kit Immulite PAP Mosaic BrainSUITE® iMRI

S*BIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute...( SINGAPORE Nov. 27 /- S*BIO Pte Lt...),Health

SBIO Expands Pipeline With the Development of a Unique Flt3 -CDK Inhibitor as a Targeted Therapy for Acute...( SINGAPORE Nov. 27 /- SBIO Pte Lt...),Health